Thursday, Merck & Co., Inc. (MRK) announced that Health Canada has approved Keytruda, also known as pembrolizumab, for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma when used alongside gemcitabine-based chemotherapy. Biliary tract carcinoma is a rare and aggressive group of cancers affecting the gallbladder and bile ducts.

周四，默克公司（Merck＆Co.，Inc.）宣布，加拿大卫生部已批准Keytruda（也称为pembrolizumab）与吉西他滨为基础的化疗联合使用，用于治疗局部晚期不可切除或转移性胆道癌的成年患者。胆道癌是一种罕见的侵袭性癌症，影响胆囊和胆管。

The company said that the approval is based on the findings of the Phase 3 KEYNOTE-966 trial, showing a significant improvement in overall survival compared to chemotherapy alone. .

该公司表示，该批准是基于第三阶段KEYNOTE-966试验的结果，与单独化疗相比，总体生存率显着提高。

Keytruda was initially sanctioned in Canada in 2015 and is now prescribed for various conditions such as advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, colorectal cancer, endometrial carcinoma, cervical cancer, esophageal cancer, triple-negative breast cancer, melanoma, and head and neck squamous cell carcinoma.

Keytruda最初于2015年在加拿大获得批准，现在用于各种疾病，如晚期肾细胞癌，膀胱癌，非小细胞肺癌，原发性纵隔B细胞淋巴瘤，经典霍奇金淋巴瘤，结直肠癌，子宫内膜癌，宫颈癌，食管癌，三阴性乳腺癌，黑色素瘤和头颈部鳞状细胞癌。